Frank M, Doss MO. Severe liver disease in proto at the cellular and the subcellular level as related to the solubility of the porphyrin. Clin Chim Acta. 1981;109:193–201.11. Kauppinen R. Porphyrias. Lancet. 2005;365:241–252.12. Grandchamp B, Puy H, Lamoril J, et al. Review: molecular and treatment of the acute porphyrias: an interdisciplinary challenge. Skin Pharmacol Appl Skin Physiol. 2001;14:393–400.3. Schultz JH. Ein fall von pemphigus leprosus, kompliziert porphyria. Curr Probl Dermatol. 1991;20:160–167.19. Gouya L, Puy H, Robreau AM, et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Med. 2002;30:27–28.20. Desnick RJ, Astrin KH. Congenital erythropoietic pathogenesis of hepatic acute porphyrias. Gastroenterol Hepatol. 1996;11:1046–1052.13. Méndez M, Poblete-Gutiérrez P, García-Bravo M, et al.

durch lepra visceralis. Greifswald: Inaugural Dissertation; 1874.4. Baumstark F. Zwei pathologische harnfarbstoffe. Pflügers porphyria: advances in pathogenesis and treatment. Br J Haematol. 2002;117:779–795.21. Roberts AG, Elder GH, de Salamanca RE, et al. A mutation

Molecular heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations in the UROD gene. Br J Dermatol. 2007;157:501–507.14. Elder GH, Human URO. D defects. In: Orfanos CE, Stadler

Archiv für Gestinale. Physiologie. 1874;9:568–584.5. Günther H. Die haematoporphyrie. Deutsches Archiv für

Klinische Medizin. 1911;105:89–146.6. Bickers DR, Frank J. The porphyrias. In: Wolff K, Goldsmith

(G281E) of the human uroporphyrinogen decarboxylase gene causes both hepatoerythropoietic porphyria and overt familial porphyria cutanea tarda: biochemical and genetic studies on Spanish patients. J Invest Dermatol. 1995;104:500–502.22. Green JJ, Manders SM. Pseudoporphyria. J Am Acad

R, Gollnick H, eds. Dermatology in Five Continents. Berlin: Springer-Verlag; 1988:857–860.15. Brady JJ, Jackson HA, Roberts AG, et al. Co-inheritance of

LA, Katz SI, eds. Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012:1228–1256.7. Aagaard L, Krag A, et al. Cutaneous porphyrias: causes, mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol. 2000;115:868–874.16. Holme SA, Whatley SD, Roberts AG, et al. Seasonal symptoms, treatments and the Danish incidence 1989–2013. Acta Derm Venereol. 2016;96:868–872.8. Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008;83:408–414.9. Kessel D. Determinants of hematoporphyrin-catalyzed

Dermatol. 2001;44:100–108.23. Murphy GM. Diseases associated with photosensitivity.

J Photochem Photobiol B. 2001;64:93–98.24. Stölzel U, Köstler E, Schuppan D, et al. Hemochromatosis palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol. 2009;129:599–605.17. Frank J, Poblete-Gutiérrez P, Neumann NJ.

(HFE) gene mutations and response to chloroquine in porphyria cutanea tarda. Arch Dermatol. 2003;139:309–313.25. Pandya AG, Nezafati KA, Ashe-Randolph M, Yalamanchili

Photosensitivity in the elderly: think of late-onset protoporphyria. J Invest Dermatol. 2013;133:1467–1471.

photosensitization. Photochem Photobiol. 1982;36:99–101.

R. Deferasirox for porphyria cutanea tarda: a pilot study. Arch Dermatol. 2012;148:898–901.

從而降低神經毒性代謝物的循環濃度。最常見的副作用為注射部位反應與噁心，且需監測肝功能檢查與血清 creatinine。Givosiran 可導致嚴重的高同半胱胺酸血症（hyperhomocysteinemia），可能因抑制對同半胱胺酸代謝重要的血基質依賴性酵素 cystathionine-β-synthase，隨後造成蛋白質-N-同半胱胺酸化（protein-N-homocysteinylation）。

tags	皮膚科, metabolic_and_systemic_diseases, porphyria, appendix, reference_laboratories, givosiran
aliases	紫質症附錄, Porphyria appendix, Porphyria reference laboratories

Dermatology Medical Library

📚 章節目錄

附錄（APPENDIX）

附錄（APPENDIX）

參考文獻（References，原文書目資料保留原文）

Table of Contents